The plasma concentration and LDL-C relationship in patients receiving ezetimibe

Journal of Clinical Pharmacology

Volumn 41, Issue 9, 2001, Pages 943-949

  Ezzet, F ^a   Wexler, D ^a   Statkevich, P ^a   Kosoglou, T ^a   Patrick, J ^a   Lipka, L ^a   Mellars, L ^a   Veltri, E ^a   Batra, V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MALE; MASS SPECTROMETRY; MIDDLE AGED;

EID: 0034865917     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010915     Document Type: Article

References (18)

1. Cholesterol and coronary disease: Outstanding questions
2. Atherogenesis and thrombosis: Mechanisms, pathogenesis and therapeutic implications
3. Screening asymptomatic adults for cardiac risk factors: The serum cholesterol level
4. Lipoproteins and atherogenesis: Current concepts
5. Effectiveness and tolerability of ezetimibe in subjects with primary hypercholesterolemia: Pooled analysis of two phase II studies
6. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
7. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH 60663
8. Kinetics of pharmacologic response: I. Proposed relationships between response and drug concentration in the intact animal and man
9. Symbolic description of factorial model for analysis of variance
10. Clinical cross-over trials in phase I
11. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects: Results of a dose-response study
12. Ezetimibe: Hypolipidemic, cholesterol absorption inhibitor
13. Novel approaches to lipid lowering: What is on the horizon?
14. Novel lipid-regulating drugs
15. Ezetimibe reduces low-density lipoprotein cholesterol: Results of a phase III, randomized, double-blind, placebo-controlled trial